How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

799 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study

Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study Donepezil, rivastigmine and galantamine are popular cholinesterase inhibitors used to manage the symptoms of Alzheimer disease and other dementias; regulatory agencies in several countries warn about a possible risk of rhabdomyolysis with donepezil, based on information from case reports. Our goal was to investigate the 30-day risk of admission to hospital with rhabdomyolysis (...) associated with initiating donepezil versus other cholinesterase inhibitors.We conducted a retrospective cohort study in Ontario, Canada, from 2002 to 2017. Participants were adults aged 66 years or older with a newly dispensed prescription for donepezil compared with rivastigmine or galantamine. The primary outcome was hospital admission with rhabdomyolysis (assessed using hospital diagnostic codes) within 30 days of a new prescription of a cholinesterase inhibitor. Odds ratios were estimated using

2019 EvidenceUpdates

2. Pharmacological aspects of galantamine for the treatment of Alzheimer's disease (PubMed)

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease 28337117 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Pharmacological aspects of galantamine for the treatment of Alzheimer's disease. 35-39 10.17179/excli2016-820 Kim Jae Kwang JK Division of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University, Incheon, 406-772, Korea. Park Sang Un SU Department of Crop Science, Chungnam National University, 99 Daehak-ro, Yuseong-gu

Full Text available with Trip Pro

2017 EXCLI journal

3. Adverse effects of galantamine, topiramate and cotrimoxazole

Adverse effects of galantamine, topiramate and cotrimoxazole Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole'', 1 July 2015 {1} {1} {1} | | > > > In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |  (...)  |   |   |  Spotlight In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole FREE DOWNLOAD All in one sample page: from serious skin reactions with Alzheimer's drug galantamine and visual field defects with topiramate to the potentially deadly effects of the antibiotic cotrimoxazole, either alone or when coadministrered with an ACE inhibitor or ARB. Sample page available for free download. Cotrimoxazole + an ACE inhibitor

2015 Prescrire

4. Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease. (PubMed)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease. Several studies have tested the N-methyl-D-aspartate-receptor antagonist memantine as an add-on to pre-existing treatment with acetylcholinesterase inhibitors. The objective of this study was to evaluate the efficacy and safety of a combined memantine and galantamine-CR de novo regimen compared with galantamine-CR only treatment (...) in never treated patients with mild-to-moderate Alzheimer's disease (AD).Antidementia drug-naïve participants (n = 232) with probable, mild-to-moderate AD, and mini-mental state examination scores between 15 and 26 (inclusive) were randomized to receive either 20 mg/day memantine plus 24 mg/day galantamine-CR or 24 mg/day galantamine-CR plus placebo in a 52-week, prospective, double-blind, controlled trial. The primary outcome measurement was the change on the Alzheimer's disease assessment scale

Full Text available with Trip Pro

2015 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: predicted high

5. Pre-sleep treatment with galantamine stimulates lucid dreaming: A double-blind, placebo-controlled, crossover study. (PubMed)

Pre-sleep treatment with galantamine stimulates lucid dreaming: A double-blind, placebo-controlled, crossover study. Lucid dreaming is a remarkable state of consciousness in which one is aware of the fact that one is dreaming while continuing to dream. Based on the strong relationship between physiological activation during rapid eye-movement sleep and lucid dreaming, our pilot research investigated whether enhancing cortical activation via acetylcholinesterease inhibition (AChEI) would (...) randomly assigned counterbalanced orders of 3 doses of galantamine (0, 4 and 8 mg). On 3 consecutive nights, they awoke approximately 4.5 hours after lights out, recalled a dream, ingested the capsules and stayed out of bed for at least 30 minutes. Participants then returned to bed and practiced the Mnemonic Induction of Lucid Dreams technique while returning to sleep. The percentage of participants who reported a lucid dream was significantly increased for both 4 mg (27%, odds ratio = 2.29) and 8 mg

Full Text available with Trip Pro

2018 PLoS ONE Controlled trial quality: uncertain

6. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer?s disease (review of TA111): a systematic review and economic model

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer?s disease (review of TA111): a systematic review and economic model The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA111): a systematic review and economic model Journals Library An error has occurred in processing the XML document An error occurred retrieving content

2012 NIHR HTA programme

7. Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice (PubMed)

Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice Neuroinflammation plays an important role in the onset and progression of neurodegenerative diseases such as Alzheimer's disease. Lipopolysaccharide (LPS, endotoxin) levels are higher in the brains of Alzheimer's disease patients and are associated with neuroinflammation and cognitive decline, while neural cholinergic signaling controls inflammation. This study (...) aimed to examine the efficacy of galantamine, a clinically approved cholinergic agent, in alleviating LPS-induced neuroinflammation and cognitive decline as well as the associated mechanism.Mice were treated with galantamine (4 mg/kg, intraperitoneal injection) for 14 days prior to LPS exposure (intracerebroventricular injection). Cognitive tests were performed, including the Morris water maze and step-through tests. mRNA expression of the microglial marker (CD11b), astrocytic marker (GFAP), and pro

Full Text available with Trip Pro

2018 Journal of neuroinflammation

8. Galantamine-memantine combination effective in dementia: Translate to dementia praecox? (PubMed)

Galantamine-memantine combination effective in dementia: Translate to dementia praecox? 29552507 2018 11 14 2215-0013 12 2018 Jun Schizophrenia research. Cognition Schizophr Res Cogn Galantamine-memantine combination effective in dementia: Translate to dementia praecox? 8-10 10.1016/j.scog.2017.11.001 Koola Maju Mathew MM Department of Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. MedOptions, Behavioral Health (...) Services, MD, USA. Mental Health Management (MHM) Services, Inc., Maryland Correctional Institutes, Maryland Department of Public Safety and Correctional Services, Jessup, MD, USA. Parsaik Ajay K AK Department of Psychiatry and Behavioral Health, Marshfield Clinic Health System, Marshfield, WI, USA. eng Journal Article 2018 01 28 United States Schizophr Res Cogn 101632223 2215-0013 Cognition Dementia Galantamine Kynurenine Memantine Schizophrenia 2017 11 10 2017 11 20 2018 3 20 6 0 2018 3 20 6 0 2018 3

Full Text available with Trip Pro

2018 Schizophrenia Research: Cognition

9. Hypothesis: apo‐lactoferrin–Galantamine Proteo‐alkaloid Conjugate for Alzheimer's disease Intervention (PubMed)

Hypothesis: apo‐lactoferrin–Galantamine Proteo‐alkaloid Conjugate for Alzheimer's disease Intervention Alzheimer's disease (AD) is known to be caused by the accumulation of deformed beta amyloid and hyperphosphorylated tau proteins resulting into formation and aggregation of senile plaques and neurofibrillary tangles in the brain. Additionally, AD is associated with the accumulation of iron or metal ions in the brain which causes oxidative stress. Galantamine (Gal) is one (...) radicals, plaques and accumulation of iron in the brain. This can be achieved by conjugating Gal with apo-lactoferrin (ApoLf), a natural compound that has high binding affinity for iron, to form an apo-lactoferrin-galantamine proteo-alkaloid conjugate (ApoLf-Gal) as a single dosage form for AD management. The conjugation is achieved through self-assembly of ApoLf which results in encapsulation of Gal. ApoLf changes its conformational structure in the presence of iron; therefore, ApoLf-Gal is proposed

Full Text available with Trip Pro

2018 Journal of cellular and molecular medicine

10. Galantamine and CBT4CBT Pilot

Galantamine and CBT4CBT Pilot Galantamine and CBT4CBT Pilot - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Galantamine and CBT4CBT Pilot The safety and scientific validity of this study (...) feasibility study to evaluate the effects of galantamine versus placebo on preventing relapse to opioid use following tapering from methadone or buprenorphine maintenance (Medication Assisted Treatment, or MAT) among adults with opioid use disorder, with additional behavioral therapy (web-based cognitive behavioral therapy) provided across all conditions to help individuals successfully transition from MAT to a drug-free state. Condition or disease Intervention/treatment Phase Methadone or Buprenorphine

2018 Clinical Trials

11. Galantamine anti-colitic effect: Role of alpha-7 nicotinic acetylcholine receptor in modulating Jak/STAT3, NF-κB/HMGB1/RAGE and p-AKT/Bcl-2 pathways (PubMed)

Galantamine anti-colitic effect: Role of alpha-7 nicotinic acetylcholine receptor in modulating Jak/STAT3, NF-κB/HMGB1/RAGE and p-AKT/Bcl-2 pathways Vagal stimulation controls systemic inflammation and modulates the immune response in different inflammatory conditions, including inflammatory bowel diseases (IBD). The released acetylcholine binds to alpha-7 nicotinic acetylcholine receptor (α7 nAChR) to suppress pro-inflammatory cytokines. This provides a new range of potential therapeutic (...) approaches for controlling inflammatory responses. The present study aimed to assess whether galantamine (Galan) anti-inflammatory action involves α7 nAChR in a 2,4,6-trinitrobenzene sulfonic acid (TNBS) model of colitis and to estimate its possible molecular pathways. Rats were assigned into normal, TNBS, sulfasalazine (Sulfz), Galan treated (10 mg/kg), methyllycaconitine (MLA; 5.6 mg/kg), and MLA + Galan groups. Drugs were administered orally once per day (11 days) and colitis was induced on the 8th

Full Text available with Trip Pro

2018 Scientific reports

12. Effects of galantamine on smoking behavior and cognitive performance in treatment-seeking smokers prior to a quit attempt. (PubMed)

Effects of galantamine on smoking behavior and cognitive performance in treatment-seeking smokers prior to a quit attempt. Drugs that enhance cholinergic transmission have demonstrated promise treating addictive disorders. Galantamine, an acetylcholinesterase inhibitor, may reduce cigarette smoking in otherwise healthy treatment-seeking smokers.The current study is a double-blind, placebo-controlled, study that randomized daily smokers (n = 60) to receive one of two doses of galantamine (...) extended release (8 or 16 mg/day), or a placebo treatment. Participants completed a smoking choice task as well as study measures and cognitive tasks in the laboratory and daily life using ecological momentary assessment. Analysis focused on smoking behavior and satisfaction, cognitive performance, and decision to smoke prior to a quit attempt.Linear mixed models demonstrated that, compared with placebo, both doses of galantamine reduced smoking in a laboratory choice task (p = 0.006) and decreased

Full Text available with Trip Pro

2018 Human psychopharmacology Controlled trial quality: uncertain

13. Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments. (PubMed)

Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments. 28705532 2018 11 13 2018 11 13 1573-2509 193 2018 03 Schizophrenia research Schizophr. Res. Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments. 459-460 S0920-9964(17)30406-1 10.1016/j.schres.2017.07.005 Koola Maju Mathew MM Department of Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, Washington (...) A Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Cambridge, MA, USA. Aaronson Scott T ST Clinical Research Program, Sheppard Pratt Health System, Baltimore, MD, USA. Kozak Rouba R Neuroscience Research Unit, Pfizer, Inc, Cambridge, MA, USA. eng ClinicalTrials.gov NCT02234752 Letter Randomized Controlled Trial Research Support, Non-U.S. Gov't 2017 07 11 Netherlands Schizophr Res 8804207 0920-9964 0 Nootropic Agents 0D3Q044KCA Galantamine 343-65-7 Kynurenine W8O17SJF3T Memantine IM

2018 Schizophrenia Research Controlled trial quality: uncertain

14. Exploring the effects of galantamine paired with meditation and dream reliving on recalled dreams: Toward an integrated protocol for lucid dream induction and nightmare resolution. (PubMed)

Exploring the effects of galantamine paired with meditation and dream reliving on recalled dreams: Toward an integrated protocol for lucid dream induction and nightmare resolution. An experimental home study examined the impact of a pre-sleep protocol for enhancing self-awareness, lucidity, and responsiveness in dreams. It included ingesting the cholinesterase inhibitor galantamine--which is widely reported to increase the frequency of lucid dreaming--prior to engaging in middle-of-the-night (...) meditation and the imaginary reliving of a distressing dream while exercising new responses. Thirty-five participants completed an eight-night study, which included pre- and post-baseline nights and six conditions: waking for 40 min before returning to bed, called Wake-Back-to-Bed (WBTB); Wake-Back-to-Bed plus placebo (WBTB + P); Wake-Back-to-Bed plus galantamine (WBTB + G); meditation and dream reliving (MDR); meditation and dream reliving plus placebo (MDR + P); and meditation and dream reliving plus

2018 Consciousness and Cognition Controlled trial quality: uncertain

15. Changes in electrophysiological markers of cognitive control after administration of galantamine (PubMed)

Changes in electrophysiological markers of cognitive control after administration of galantamine The healthy brain is able to maintain a stable balance between bottom-up sensory processing and top-down cognitive control. The neurotransmitter acetylcholine plays a substantial role in this. Disruption of this balance could contribute to symptoms occurring in psychosis, including subtle disruption of motor control and aberrant appropriation of salience to external stimuli; however the pathological (...) mechanisms are poorly understood. On account of the role beta oscillations play in mediating cognitive control, investigation of beta oscillations is potentially informative about such mechanisms. Here, we used magnetoencephalography to investigate the effect of the acetylcholinesterase-inhibitor, galantamine, on beta oscillations within the sensorimotor region during both a sensorimotor task and a relevance-modulation task in healthy participants, employing a double blind randomized placebo controlled

Full Text available with Trip Pro

2018 NeuroImage : Clinical Controlled trial quality: uncertain

16. Effect of Galantamine on Inflammation and Cognition

Effect of Galantamine on Inflammation and Cognition Effect of Galantamine on Inflammation and Cognition - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of Galantamine on Inflammation and Cognition (...) : National Institute on Drug Abuse (NIDA) Information provided by (Responsible Party): University of Pennsylvania Study Details Study Description Go to Brief Summary: This study tests whether galantamine (GAL) reduces HIV-related inflammation and cognitive deficits. In this double-blind placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers and 60 non-smokers) will be randomized to 12 weeks of GAL or placebo, followed by a 4-week washout, then 12 weeks of GAL or placebo (arms

2017 Clinical Trials

17. Long-term effect of galantamine on cognitive function in patients with Alzheimer’s disease versus a simulated disease trajectory: an observational study in the clinical setting (PubMed)

Long-term effect of galantamine on cognitive function in patients with Alzheimer’s disease versus a simulated disease trajectory: an observational study in the clinical setting Long-term maintenance of cognitive function is an important goal of treatment for Alzheimer's disease (AD), but evidence about the long-term efficacy of cholinesterase inhibitors is sparse. To evaluate the long-term efficacy and safety of galantamine for AD in routine clinical practice, we conducted a 72-week post (...) -marketing surveillance study. The effect of galantamine on cognitive function was estimated in comparison with a simulated disease trajectory.Patients with mild-to-moderate AD received flexible dosing of galantamine (16-24 mg/day) during this study. Cognitive function was assessed by the mini mental state examination (MMSE) and the clinical status was determined by the Clinical Global Impression-Improvement (CGI-I). Changes of the MMSE score without treatment were estimated in each patient using

Full Text available with Trip Pro

2017 Neuropsychiatric disease and treatment

18. Galantamine and Environmental Enrichment Enhance Cognitive Recovery after Experimental Traumatic Brain Injury But Do Not Confer Additional Benefits When Combined (PubMed)

Galantamine and Environmental Enrichment Enhance Cognitive Recovery after Experimental Traumatic Brain Injury But Do Not Confer Additional Benefits When Combined Environmental enrichment (EE) enhances cognition after traumatic brain injury (TBI). Galantamine (GAL) is an acetylcholinesterase inhibitor that also may promote benefits. Hence, the aims of this study were to assess the efficacy of GAL alone (standard [STD] housing) and in combination with EE in adult male rats after TBI

Full Text available with Trip Pro

2017 Journal of neurotrauma

19. Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease (PubMed)

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease 28761423 2018 11 13 1673-5374 12 6 2017 Jun Neural regeneration research Neural Regen Res Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease. 916-917 10.4103/1673-5374.208572 Castillo Willian O WO 0000-0001-9138-1248 Department of Biology, University of Cauca, Popayan, Colombia. Aristizabal-Pachon Andres Felipe AF Department of Genetics

Full Text available with Trip Pro

2017 Neural Regeneration Research

20. Ascorbic acid tethered polymeric nanoparticles enable efficient brain delivery of galantamine: An in vitro-in vivo study (PubMed)

Ascorbic acid tethered polymeric nanoparticles enable efficient brain delivery of galantamine: An in vitro-in vivo study The aim of this work was to enhance the transportation of the galantamine to the brain via ascorbic acid grafted PLGA-b-PEG nanoparticles (NPs) using SVCT2 transporters of choroid plexus. PLGA-b-PEG copolymer was synthesized and characterized by 1H NMR, gel permeation chromatography, and differential scanning calorimetry. PLGA-b-PEG-NH2 and PLGA-b-mPEG NPs were prepared

Full Text available with Trip Pro

2017 Scientific reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>